These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32990681)

  • 1. Canagliflozin extends life span in genetically heterogeneous male but not female mice.
    Miller RA; Harrison DE; Allison DB; Bogue M; Debarba L; Diaz V; Fernandez E; Galecki A; Garvey WT; Jayarathne H; Kumar N; Javors MA; Ladiges WC; Macchiarini F; Nelson J; Reifsnyder P; Rosenthal NA; Sadagurski M; Salmon AB; Smith DL; Snyder JM; Lombard DB; Strong R
    JCI Insight; 2020 Nov; 5(21):. PubMed ID: 32990681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM-HET3 mice.
    Jayarathne HSM; Debarba LK; Jaboro JJ; Ginsburg BC; Miller RA; Sadagurski M
    Aging Cell; 2022 Jul; 21(7):e13653. PubMed ID: 35707855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex-dependent effects of Canagliflozin on kidney protection in mice with combined hypertension-type 1 diabetes.
    Trentin-Sonoda M; Cheff V; Gutsol A; Hébert RL
    PLoS One; 2023; 18(12):e0295284. PubMed ID: 38055691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of canagliflozin treatment on the skeleton of aged UM-HET3 mice.
    Yildirim G; Bergamo ETP; Poudel SB; Ruff RR; Dixit M; Hu B; Mijares DQ; Witek L; Chlebek C; Harrison DE; Strong R; Miller RA; Ladiges W; Bromage TG; Rosen CJ; Yakar S
    Geroscience; 2023 Jun; 45(3):1933-1951. PubMed ID: 37166526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
    Shao M; Chen D; Wang Q; Guo F; Wei F; Zhang W; Gan T; Luo Y; Fan X; Du P; Liu Y; Ma X; Ren G; Song Y; Zhao Y; Qin G
    Diabetologia; 2024 Apr; 67(4):738-754. PubMed ID: 38236410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canagliflozin alleviates LPS-induced acute lung injury by modulating alveolar macrophage polarization.
    Lin F; Song C; Zeng Y; Li Y; Li H; Liu B; Dai M; Pan P
    Int Immunopharmacol; 2020 Nov; 88():106969. PubMed ID: 33182027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following
    Korkmaz-Icöz S; Kocer C; Sayour AA; Kraft P; Benker MI; Abulizi S; Georgevici AI; Brlecic P; Radovits T; Loganathan S; Karck M; Szabó G
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
    Woods TC; Satou R; Miyata K; Katsurada A; Dugas CM; Klingenberg NC; Fonseca VA; Navar LG
    Am J Nephrol; 2019; 49(4):331-342. PubMed ID: 30921791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits.
    Thrailkill KM; Bunn RC; Uppuganti S; Ray P; Popescu I; Kalaitzoglou E; Fowlkes JL; Nyman JS
    Bone; 2020 Dec; 141():115625. PubMed ID: 32890778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.
    Thrailkill KM; Nyman JS; Bunn RC; Uppuganti S; Thompson KL; Lumpkin CK; Kalaitzoglou E; Fowlkes JL
    Bone; 2017 Jan; 94():141-151. PubMed ID: 27989651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice.
    Nasiri-Ansari Ν; Dimitriadis GK; Agrogiannis G; Perrea D; Kostakis ID; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
    Cardiovasc Diabetol; 2018 Jul; 17(1):106. PubMed ID: 30049285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin impairs blood reperfusion of ischaemic lower limb partially by inhibiting the retention and paracrine function of bone marrow derived mesenchymal stem cells.
    Lin Y; Nan J; Shen J; Lv X; Chen X; Lu X; Zhang C; Xiang P; Wang Z; Li Z
    EBioMedicine; 2020 Feb; 52():102637. PubMed ID: 31981975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells.
    Satou R; Cypress MW; Woods TC; Katsurada A; Dugas CM; Fonseca VA; Navar LG
    Am J Physiol Renal Physiol; 2020 Jan; 318(1):F67-F75. PubMed ID: 31682172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canagliflozin retards age-related lesions in heart, kidney, liver, and adrenal gland in genetically heterogenous male mice.
    Snyder JM; Casey KM; Galecki A; Harrison DE; Jayarathne H; Kumar N; Macchiarini F; Rosenthal N; Sadagurski M; Salmon AB; Strong R; Miller RA; Ladiges W
    Geroscience; 2023 Feb; 45(1):385-397. PubMed ID: 35974129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canagliflozin Increases Intestinal Adenoma Burden in Female ApcMin/+ Mice.
    Korfhage J; Skinner ME; Basu J; Greenson JK; Miller RA; Lombard DB
    J Gerontol A Biol Sci Med Sci; 2022 Feb; 77(2):215-220. PubMed ID: 34448851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells.
    Uthman L; Kuschma M; Römer G; Boomsma M; Kessler J; Hermanides J; Hollmann MW; Preckel B; Zuurbier CJ; Weber NC
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1083-1094. PubMed ID: 33048256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
    Nakano D; Kawaguchi T; Iwamoto H; Hayakawa M; Koga H; Torimura T
    PLoS One; 2020; 15(4):e0232283. PubMed ID: 32343721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms.
    Osataphan S; Macchi C; Singhal G; Chimene-Weiss J; Sales V; Kozuka C; Dreyfuss JM; Pan H; Tangcharoenpaisan Y; Morningstar J; Gerszten R; Patti ME
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex-dependent effects of canagliflozin and dapagliflozin on hemostasis in normoglycemic and hyperglycemic mice.
    Marcińczyk N; Misztal T; Chabielska E; Gromotowicz-Popławska A
    Sci Rep; 2023 Jan; 13(1):932. PubMed ID: 36650229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypothalamic sex-specific metabolic shift by canagliflozin during aging.
    Jayarathne HSM; Sullivan R; Stilgenbauer L; Debarba LK; Kuchumov A; Koshko L; Scofield S; Liu W; Ginsburg BC; Miller RA; Sadagurski M
    Geroscience; 2024 May; ():. PubMed ID: 38801647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.